GSK’s Vallance Teams Up With Ex-University London Colleagues In Pentraxin Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal for amyloidosis program shows GSK’s small-unit R&D structure at work.
You may also be interested in...
GSK Argues Its Strategy Is Delivering As It Makes More Cuts, Including In R&D
GlaxoSmithKline CEO Andrew Witty declared on Feb. 4 that his strategy of building a global, diversified business was delivering. And to prove his point, he announced a return to full-year sales growth in 2009 after a negative 2008, and an upbeat forecast for 2010 as well
GSK Argues Its Strategy Is Delivering As It Makes More Cuts, Including In R&D
GlaxoSmithKline CEO Andrew Witty declared on Feb. 4 that his strategy of building a global, diversified business was delivering. And to prove his point, he announced a return to full-year sales growth in 2009 after a negative 2008, and an upbeat forecast for 2010 as well
GSK Argues Its Strategy Is Delivering As Still More Cuts Are Made, Including in R&D
CEO Witty suggests group has emerged from worst of patent storm with an upbeat forecast for 2010 and promises of further cost-cutting.